UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange...
SCHEDULE 13G Amendment No. 7 ZAFGEN INC COMMON STOCK Cusip #98885E103 Check the appropriate box to designate the rule...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendmen...
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED...
BOSTON, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHED...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
Agreement reached with U.S. FDA on in vivo animal study design and protocol to translate work from novel in...
BOSTON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical...
Alignment reached on in vivo animal study design and protocol to translate work from novel in vitro assays and...
us98885e1038_071019.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.